• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶血尿毒综合征伴神经功能障碍患儿接受依库珠单抗治疗的脑磁共振成像模式和结局。

Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab.

机构信息

Pediatric Neurology Department, Necker-Enfants Malades Hospital, APHP, Paris, France.

出版信息

Dev Med Child Neurol. 2013 Aug;55(8):758-65. doi: 10.1111/dmcn.12161. Epub 2013 May 10.

DOI:10.1111/dmcn.12161
PMID:23659643
Abstract

AIM

The aim of this study was to describe the magnetic resonance imaging (MRI) findings and the neurological and neuropsychological outcomes in paediatric, diarrhoea-associated haemolytic-uraemic syndrome (D+HUS) with central nervous system impairment treated with eculizumab, a monoclonal antibody.

METHOD

The 14-month single-centre prospective study included seven children (three males, four females; age range 16 mo-7 y 8 mo; median age 3 y 7 mo) with typical D+HUS and acute neurological impairment. In the acute phase of the disease, neurological assessment and brain magnetic resonance imaging (MRI), including measurement of the apparent diffusion coefficient (ADC), were performed, and neuropsychological evaluation and brain MRI were also carried out 6 months after disease onset.

RESULTS

In the acute phase, basal ganglia and white matter abnormalities with ADC restriction were a common and reversible MRI finding. In all the surviving patients (5/7), follow-up MRI after 6 months was normal, indicating reversible lesions. Clinical and neuropsychological evaluations after 6 months were also normal.

INTERPRETATION

This specific brain MRI pattern consisting of an ADC decrease in basal ganglia and white matter without major T2/fluid-attenuated inversion recovery (FLAIR) injury may be a key finding in the acute phase of the disease in favour of a vasculitis hypothesis. These reversible lesions were associated with a good neurological outcome. These results call for further evaluation of the potential role of eculizumab in the choice of treatment for severe D+HUS, particularly in the case of early neurological signs.

摘要

目的

本研究旨在描述磁共振成像(MRI)表现以及接受依库珠单抗(一种单克隆抗体)治疗的伴有中枢神经系统损伤的儿童腹泻相关性溶血尿毒综合征(D+HUS)的神经和神经心理学结局。

方法

这是一项 14 个月的单中心前瞻性研究,纳入了 7 名(3 男 4 女;年龄 16 月-7 岁 8 月;中位年龄 3 岁 7 月)具有典型 D+HUS 和急性神经功能障碍的儿童。在疾病的急性期,进行了神经学评估和脑 MRI,包括表观扩散系数(ADC)测量,还在发病后 6 个月进行了神经心理学评估和脑 MRI。

结果

在急性期,基底节和白质异常伴 ADC 受限是常见且可逆的 MRI 发现。在所有存活的患者(5/7)中,6 个月后的随访 MRI 均正常,表明病变可逆。6 个月后的临床和神经心理学评估也正常。

结论

这种由基底节和白质 ADC 降低而无明显 T2/液体衰减反转恢复(FLAIR)损伤组成的特定脑 MRI 模式可能是疾病急性期支持血管炎假说的关键发现。这些可逆性病变与良好的神经结局相关。这些结果呼吁进一步评估依库珠单抗在治疗严重 D+HUS 中的潜在作用,特别是在出现早期神经症状的情况下。

相似文献

1
Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab.溶血尿毒综合征伴神经功能障碍患儿接受依库珠单抗治疗的脑磁共振成像模式和结局。
Dev Med Child Neurol. 2013 Aug;55(8):758-65. doi: 10.1111/dmcn.12161. Epub 2013 May 10.
2
A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.小儿神经评估评分可能会驱动基于依库珠单抗的治疗,用于治疗伴有神经系统受累的大肠杆菌相关溶血尿毒综合征。
Pediatr Nephrol. 2019 Mar;34(3):517-527. doi: 10.1007/s00467-018-4112-2. Epub 2018 Oct 25.
3
Diffusion-weighted imaging findings in hemolytic uremic syndrome with central nervous system involvement.溶血尿毒综合征合并中枢神经系统受累的弥散加权成像表现
J Child Neurol. 2009 Feb;24(2):247-50. doi: 10.1177/0883073808323022. Epub 2008 Dec 12.
4
Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.舒巴坦酶相关溶血尿毒综合征患儿接受依库珠单抗治疗的结局:一项匹配队列研究。
Nephrol Dial Transplant. 2020 Dec 4;35(12):2147-2153. doi: 10.1093/ndt/gfz158.
5
Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.依库珠单抗治疗伴有神经受累的典型溶血性尿毒症综合征(HUS)
Medicine (Baltimore). 2015 Jun;94(24):e1000. doi: 10.1097/MD.0000000000001000.
6
CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings.伴有中枢神经系统受累的溶血尿毒综合征的CT和MRI:病变分布及影像学表现的预后价值
Pediatr Radiol. 2004 Oct;34(10):805-10. doi: 10.1007/s00247-004-1289-2. Epub 2004 Jul 29.
7
Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.依库珠单抗治疗非典型溶血性尿毒综合征和其他补体介导的肾脏疾病。
Curr Opin Pediatr. 2013 Apr;25(2):225-31. doi: 10.1097/MOP.0b013e32835df4a3.
8
Patterns in early diffusion-weighted MRI in children with haemolytic uraemic syndrome and CNS involvement.儿童溶血尿毒综合征伴中枢神经系统受累的早期弥散加权 MRI 模式。
Eur Radiol. 2012 Mar;22(3):506-13. doi: 10.1007/s00330-011-2286-0. Epub 2011 Oct 8.
9
A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.非典型溶血尿毒综合征诊断与治疗的新时代。
Neth J Med. 2012 Apr;70(3):121-9.
10
Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.依库珠单抗治疗严重小儿 STEC-HUS:一项多中心回顾性研究。
Pediatr Nephrol. 2018 Aug;33(8):1385-1394. doi: 10.1007/s00467-018-3903-9. Epub 2018 Mar 23.

引用本文的文献

1
Characterizing the association between complement-mediated TMA and cognitive dysfunction using MRI and neurocognitive assessment.使用磁共振成像(MRI)和神经认知评估来表征补体介导的血栓性微血管病(TMA)与认知功能障碍之间的关联。
Blood Vessel Thromb Hemost. 2024 Jun 24;1(3):100016. doi: 10.1016/j.bvth.2024.100016. eCollection 2024 Sep.
2
Pericardial effusion in pediatric Shiga toxin-producing E. coli hemolytic uremic syndrome: a French multicentre study.产志贺毒素大肠杆菌溶血尿毒综合征患儿的心包积液:一项法国多中心研究
Pediatr Nephrol. 2025 Jul 22. doi: 10.1007/s00467-025-06877-0.
3
IgG-immunoadsorptions and eculizumab combination in STEC-hemolytic and uremic syndrome pediatric patients with neurological involvement.
IgG免疫吸附与依库珠单抗联合用于伴有神经受累的产志贺毒素大肠杆菌溶血尿毒综合征儿科患者
Pediatr Nephrol. 2025 Feb;40(2):431-440. doi: 10.1007/s00467-024-06418-1. Epub 2024 Sep 19.
4
Neurological involvement in hematopoietic stem cell transplantation-associated thrombotic microangiopathy.造血干细胞移植相关性血栓性微血管病的神经学表现。
Ann Hematol. 2024 Sep;103(9):3303-3313. doi: 10.1007/s00277-024-05798-6. Epub 2024 May 20.
5
Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.产志贺毒素大肠埃希菌溶血尿毒综合征应用依库珠单抗治疗:系统评价。
Pediatr Nephrol. 2024 May;39(5):1369-1385. doi: 10.1007/s00467-023-06216-1. Epub 2023 Dec 6.
6
Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities.儿童肾脏疾病中的补体抑制剂:新的治疗机遇
Pediatr Nephrol. 2024 May;39(5):1387-1404. doi: 10.1007/s00467-023-06120-8. Epub 2023 Sep 21.
7
Cerebral microstructural changes in children suffering from hemolytic uremic syndrome.儿童溶血尿毒综合征的脑微观结构变化。
Eur J Pediatr. 2023 Oct;182(10):4663-4672. doi: 10.1007/s00431-023-05130-w. Epub 2023 Aug 10.
8
Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement.依库珠单抗治疗产志贺毒素大肠杆菌相关溶血尿毒综合征:小儿神经受累患者治疗模式的转变
Pediatr Nephrol. 2024 Jan;39(1):315-324. doi: 10.1007/s00467-023-06102-w. Epub 2023 Jul 25.
9
HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.一名 4 岁女孩因 CFH 和产志贺毒素大肠杆菌感染的 HUS 接受依库珠单抗治疗。
Pediatr Nephrol. 2023 Apr;38(4):1195-1203. doi: 10.1007/s00467-022-05694-z. Epub 2022 Aug 15.
10
Eculizumab Use in a Temporarily Dialysis-Dependent Patient With Shiga Toxin-Producing Hemolytic Uremic Syndrome With Neurological Complications.依库珠单抗在一名依赖临时透析的产志贺毒素溶血尿毒综合征伴神经系统并发症患者中的应用。
J Pediatr Pharmacol Ther. 2022;27(1):90-95. doi: 10.5863/1551-6776-27.1.90. Epub 2021 Dec 22.